Anzeige
Mehr »
Dienstag, 30.09.2025 - Börsentäglich über 12.000 News
Das Geheimnis der Wall Street: Diese Kupferaktie wird bewertet wie ein Nobody - hat aber das Zeug zum Giganten
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14M2J | ISIN: IE00BTN1Y115 | Ticker-Symbol: 2M6
Tradegate
30.09.25 | 16:54
80,52 Euro
+0,47 % +0,38
1-Jahres-Chart
MEDTRONIC PLC Chart 1 Jahr
5-Tage-Chart
MEDTRONIC PLC 5-Tage-Chart
RealtimeGeldBriefZeit
80,4880,5317:06
80,4680,5317:06
ACCESS Newswire
147 Leser
Artikel bewerten:
(0)

Medtronic Joins U.N. Call to Action Against High Blood Pressure

United Nations recommends "utmost urgency" in dealing with the disease

NORTHAMPTON, MA / ACCESS Newswire / September 30, 2025 / The United Nations (U.N.) called on member nations to commit "with the utmost urgency" to an ambitious goal of fast-tracking progress in fighting mental health issues and non-communicable diseases (NCDs), particularly high blood pressure-the largest risk factor for premature death in the world.

"We therefore commit, with the utmost urgency, to preventing and scaling up effective treatment of hypertension so that 150 million more people have hypertension under control by 2030," the U.N. said in its declaration.

Hypertension, or high blood pressure, is the leading preventable cause of cardiovascular deaths, including stroke, heart attack, sudden death, heart failure, and end-stage renal disease.1 And the problem is rapidly worsening. Globally, 1.3 billion adults are living with hypertension, double the number since 1990. And only 1 in 5 (about 260 million) have it under control, according to the U.N.

"Current approaches to hypertension control are not enough," said Jason Weidman, Senior Vice President and President, Coronary & Renal Denervation, at Medtronic. "But a new and promising field is emerging. One in which technological advancements can be harnessed for the treatment of uncontrolled hypertension, offering new hope to patients managing this global health challenge."

Weidman joined a U.N. panel discussion focused on the need for action and how recently developed medical technology might help reach the U.N. goals.

For decades, medication and lifestyle changes were the only treatments for high blood pressure. But in November of 2023, the U.S. Food and Drug Administration approved the first-ever medical device procedures to treat high blood pressure. The Medtronic therapy is know as the Symplicity Spyral renal denervation procedure. See how it works.

"Medications and lifestyle changes were an effective approach for many but left a significant number of patients at elevated risk due to challenges with long-term medication adherence," Dr. Taisei Kobayashi, Interventional Cardiologist at the University of Pennsylvania, told the U.N. panel. "The Symplicity Spyral renal denervation system - a one-time, minimally invasive procedure - can help patients with uncontrolled hypertension reduce their blood pressure."*

The Medtronic Symplicity Spyral renal denervation procedure delivers radio frequency energy to nerves near the kidneys that can become overactive and contribute to high blood pressure. It's now approved for commercial use in more than 75 countries around the world. See how the Symplicity blood pressure procedure helped Paul Griffin.

"We stand ready to integrate our renal denervation technology into both public and private healthcare systems," Weidman said. "We're prepared to partner at every level of care. Let us seize this opportunity to transform the landscape of NCDs, harness the power of innovation, and improve the health of generations to come."

The U.N. declaration came at the Fourth High-level Meeting of the UN General Assembly on the prevention and control of NCDs and the promotion of mental health and well-being on Sept. 25. In addition to high blood pressure, the declaration also set worldwide goals of making access to mental health care available to 150 million more people by 2030, and reducing the number of people using tobacco, also by 150 million before 2030.

*Any views expressed by Dr. Kobayashi solely reflect personal opinion and do not reflect the views or opinions held by the University of Pennsylvania.

Important safety information about the Symplicity Spyral procedure can be found at BeyondHBP.com.

1WHO. Hypertension fact sheet. September 13, 2019. Available at: https://www.who.int/news-room/fact-sheets/detail/hypertension . Accessed February 15, 2022.

Paul Griffin checks his blood pressure at home

View additional multimedia and more ESG storytelling from Medtronic on 3blmedia.com.

Contact Info:
Spokesperson: Medtronic
Website: https://www.3blmedia.com/profiles/medtronic
Email: info@3blmedia.com

SOURCE: Medtronic



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/industrial-and-manufacturing/medtronic-joins-u.n.-call-to-action-against-high-blood-pressure-1079898

© 2025 ACCESS Newswire
Epische Goldpreisrallye
Der Goldpreis hat ein neues Rekordhoch überschritten. Die Marke von 3.500 US-Dollar ist gefallen, und selbst 4.000 US-Dollar erscheinen nur noch als Zwischenziel.

Die Rallye wird von mehreren Faktoren gleichzeitig getrieben:
  • · massive Käufe durch Noten- und Zentralbanken
  • · Kapitalflucht in sichere Häfen
  • · hohe Nachfrage nach physisch besicherten Gold-ETFs
  • · geopolitische Unsicherheit und Inflationssorgen

Die Aktienkurse vieler Goldproduzenten und Explorer sind in den vergangenen Wochen regelrecht explodiert.

Doch es gibt noch Titel, die Nachholpotenzial besitzen. In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Goldaktien jetzt besonders aussichtsreich sind und warum der Aufwärtstrend noch lange nicht vorbei sein dürfte.

Laden Sie jetzt den Spezialreport kostenlos herunter und profitieren Sie von der historischen Gold-Hausse.

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.